Company intelligence / Profile preview

Stereo Biotherapeutics

Montreal, Quebec, Canadalinkedin.com ↗

Ownership: Private
Employees: ~6
Development stage: Preclinical

Overview

Stereo Biotherapeutics develops multi-specific therapeutics targeting orphan and immune-mediated diseases. Their lead program, ST‑002, targets Cushing’s syndrome with potential expansion into NASH. Another program, ST‑003, addresses Primary Sclerosing Cholangitis and may also impact IBD. The company has a Cooperative Research and Development Agreement with the NIH for its lead asset but has not yet reported late-stage clinical results.

Therapeutic areas: GastroenterologyEndocrinology
Modalities: Multi-specific pMHC-targeting therapeuticsSmall molecules or biologic drugs (inferred from therapeutic focus)
Industry: Biotech

Partnerships

National Institutes of Health (NIH) – Cooperative Research and Development Agreement for Cushing's Syndrome therapy development

Beyond the preview

Go deeper on Stereo Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stereo Biotherapeutics.

Explore the full profile